Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Portfolio Pulse from
Xenetic Biosciences, Inc. presented positive preclinical data on the co-administration of DNase I with CAR T cells, showing potential in treating melanoma lung metastasis. This data supports the use of DNase I to enhance CAR T cell therapy efficacy.
November 21, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenetic Biosciences presented promising preclinical data on DNase I and CAR T cells, potentially enhancing cancer treatment efficacy. This could positively impact the company's stock as it advances its immune-oncology technologies.
The presentation of positive preclinical data suggests potential advancements in Xenetic's cancer treatment technologies, which could lead to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100